Unknown

Dataset Information

0

Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation.


ABSTRACT: Myocardial ischemia-reperfusion (IR) injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction (AMI), in which the recruitment of inflammatory monocytes plays a causative role. Here we develop bioabsorbable poly-lactic/glycolic acid (PLGA) nanoparticles incorporating irbesartan, an angiotensin II type 1 receptor blocker with a peroxisome proliferator-activated receptor (PPAR)? agonistic effect (irbesartan-NP). In a mouse model of IR injury, intravenous PLGA nanoparticles distribute to the IR myocardium and monocytes in the blood and in the IR heart. Single intravenous treatment at the time of reperfusion with irbesartan-NP (3.0?mg kg(-1) irbesartan), but not with control nanoparticles or irbesartan solution (3.0?mg kg(-1)), inhibits the recruitment of inflammatory monocytes to the IR heart, and reduces the infarct size via PPAR?-dependent anti-inflammatory mechanisms, and ameliorates left ventricular remodeling 21 days after IR. Irbesartan-NP is a novel approach to treat myocardial IR injury in patients with AMI.

SUBMITTER: Nakano Y 

PROVIDER: S-EPMC4939605 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation.

Nakano Yasuhiro Y   Matoba Tetsuya T   Tokutome Masaki M   Funamoto Daiki D   Katsuki Shunsuke S   Ikeda Gentaro G   Nagaoka Kazuhiro K   Ishikita Ayako A   Nakano Kaku K   Koga Jun-Ichiro J   Sunagawa Kenji K   Egashira Kensuke K  

Scientific reports 20160711


Myocardial ischemia-reperfusion (IR) injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction (AMI), in which the recruitment of inflammatory monocytes plays a causative role. Here we develop bioabsorbable poly-lactic/glycolic acid (PLGA) nanoparticles incorporating irbesartan, an angiotensin II type 1 receptor blocker with a peroxisome proliferator-activated receptor (PPAR)γ agonistic effect (irbesartan-NP). In a mouse model of IR injury, intravenous PLG  ...[more]

Similar Datasets

| S-EPMC8602362 | biostudies-literature
| S-EPMC8477875 | biostudies-literature
| S-EPMC4748220 | biostudies-literature
| S-EPMC9426742 | biostudies-literature
| S-EPMC11306229 | biostudies-literature
| S-EPMC7649428 | biostudies-literature
| S-EPMC7582178 | biostudies-literature
| S-EPMC5650379 | biostudies-literature
| S-EPMC5116669 | biostudies-literature
| S-EPMC8336489 | biostudies-literature